Article Details
Retrieved on: 2021-08-07 19:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here